Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry

Tzu Chuan Huang, Shang Yi Huang, Ming Yao, Chen Yuan Lin, Wen Li Hwang, Jyh Pyng Gau, Tran Der Tan, Po Nan Wang, Yi Chang Liu, Shih Chiang Lin, Ruey Ho Kao, Sung Nan Pei, Ming Sun Yu, Hsuan Yu Lin, Yung Cheng Su, Chih Cheng Chen, Sin Syue Li, Yi Ying Wu

Research output: Contribution to journalArticle

Abstract

© 2018 Background/Purpose: Multiple myeloma (MM) is a monoclonal plasma cell malignancy. The primary choice of treatment for MM is induction therapy followed by autologous stem cell transplantation (ASCT). This study aimed to analyze the treatment efficacy of ASCT in a Taiwanese cohort and evaluate possible prognostic factors. Methods: From the database of the Taiwan Blood and Marrow Transplantation registry, data on 396 patients with MM who underwent ASCT were reviewed. Results: The average age of participants was 54.8 years, and there were more men than women (57.6% vs. 42.4%). Most patients were diagnosed with IgG-type myeloma (52.4%), followed by IgA-type (23.2%) and light-chain type (21.4%). Patients with Durie Salmon Staging System (DSS) III disease accounted for 61.9% of the study cohort, while 23.7% had stage II and 14.4% had stage I disease. The median progression-free survival (PFS) and overall survival (OS) after ASCT were 46.5 months and 70.4 months, respectively. DSS III was a poor prognostic factor affecting both PFS and OS with a duration of 35.9 months and 69.0 months, respectively, compared with the other two stages (p = 0.006 and p = 0.03, respectively). In addition, patients with better treatment response before ASCT had better PFS and OS compared with those who did not show a response (both p < 0.0001). The overall incidence of organ toxicities associated with transplantation was low. Conclusion: In conclusion, our cohort showed that myeloma patients with early DSS and better treatment response before ASCT had better long-term survival outcomes.
Original languageEnglish
JournalJournal of the Formosan Medical Association
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Taiwan
Registries
Transplantation
Bone Marrow
Transplants
Salmon
Disease-Free Survival
Survival
Therapeutics
Plasma Cells
Immunoglobulin A
Cohort Studies
Immunoglobulin G
Databases
Light
Incidence
Neoplasms

Keywords

  • Multiple myeloma
  • Survival
  • Transplantation

Cite this

Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry. / Huang, Tzu Chuan; Huang, Shang Yi; Yao, Ming; Lin, Chen Yuan; Hwang, Wen Li; Gau, Jyh Pyng; Tan, Tran Der; Wang, Po Nan; Liu, Yi Chang; Lin, Shih Chiang; Kao, Ruey Ho; Pei, Sung Nan; Yu, Ming Sun; Lin, Hsuan Yu; Su, Yung Cheng; Chen, Chih Cheng; Li, Sin Syue; Wu, Yi Ying.

In: Journal of the Formosan Medical Association, 01.01.2018.

Research output: Contribution to journalArticle

Huang, TC, Huang, SY, Yao, M, Lin, CY, Hwang, WL, Gau, JP, Tan, TD, Wang, PN, Liu, YC, Lin, SC, Kao, RH, Pei, SN, Yu, MS, Lin, HY, Su, YC, Chen, CC, Li, SS & Wu, YY 2018, 'Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry', Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2018.07.020
Huang, Tzu Chuan ; Huang, Shang Yi ; Yao, Ming ; Lin, Chen Yuan ; Hwang, Wen Li ; Gau, Jyh Pyng ; Tan, Tran Der ; Wang, Po Nan ; Liu, Yi Chang ; Lin, Shih Chiang ; Kao, Ruey Ho ; Pei, Sung Nan ; Yu, Ming Sun ; Lin, Hsuan Yu ; Su, Yung Cheng ; Chen, Chih Cheng ; Li, Sin Syue ; Wu, Yi Ying. / Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry. In: Journal of the Formosan Medical Association. 2018.
@article{83174fbf77844abab25886bbfa3a5bde,
title = "Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry",
abstract = "{\circledC} 2018 Background/Purpose: Multiple myeloma (MM) is a monoclonal plasma cell malignancy. The primary choice of treatment for MM is induction therapy followed by autologous stem cell transplantation (ASCT). This study aimed to analyze the treatment efficacy of ASCT in a Taiwanese cohort and evaluate possible prognostic factors. Methods: From the database of the Taiwan Blood and Marrow Transplantation registry, data on 396 patients with MM who underwent ASCT were reviewed. Results: The average age of participants was 54.8 years, and there were more men than women (57.6{\%} vs. 42.4{\%}). Most patients were diagnosed with IgG-type myeloma (52.4{\%}), followed by IgA-type (23.2{\%}) and light-chain type (21.4{\%}). Patients with Durie Salmon Staging System (DSS) III disease accounted for 61.9{\%} of the study cohort, while 23.7{\%} had stage II and 14.4{\%} had stage I disease. The median progression-free survival (PFS) and overall survival (OS) after ASCT were 46.5 months and 70.4 months, respectively. DSS III was a poor prognostic factor affecting both PFS and OS with a duration of 35.9 months and 69.0 months, respectively, compared with the other two stages (p = 0.006 and p = 0.03, respectively). In addition, patients with better treatment response before ASCT had better PFS and OS compared with those who did not show a response (both p < 0.0001). The overall incidence of organ toxicities associated with transplantation was low. Conclusion: In conclusion, our cohort showed that myeloma patients with early DSS and better treatment response before ASCT had better long-term survival outcomes.",
keywords = "Multiple myeloma, Survival, Transplantation",
author = "Huang, {Tzu Chuan} and Huang, {Shang Yi} and Ming Yao and Lin, {Chen Yuan} and Hwang, {Wen Li} and Gau, {Jyh Pyng} and Tan, {Tran Der} and Wang, {Po Nan} and Liu, {Yi Chang} and Lin, {Shih Chiang} and Kao, {Ruey Ho} and Pei, {Sung Nan} and Yu, {Ming Sun} and Lin, {Hsuan Yu} and Su, {Yung Cheng} and Chen, {Chih Cheng} and Li, {Sin Syue} and Wu, {Yi Ying}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jfma.2018.07.020",
language = "English",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",

}

TY - JOUR

T1 - Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry

AU - Huang, Tzu Chuan

AU - Huang, Shang Yi

AU - Yao, Ming

AU - Lin, Chen Yuan

AU - Hwang, Wen Li

AU - Gau, Jyh Pyng

AU - Tan, Tran Der

AU - Wang, Po Nan

AU - Liu, Yi Chang

AU - Lin, Shih Chiang

AU - Kao, Ruey Ho

AU - Pei, Sung Nan

AU - Yu, Ming Sun

AU - Lin, Hsuan Yu

AU - Su, Yung Cheng

AU - Chen, Chih Cheng

AU - Li, Sin Syue

AU - Wu, Yi Ying

PY - 2018/1/1

Y1 - 2018/1/1

N2 - © 2018 Background/Purpose: Multiple myeloma (MM) is a monoclonal plasma cell malignancy. The primary choice of treatment for MM is induction therapy followed by autologous stem cell transplantation (ASCT). This study aimed to analyze the treatment efficacy of ASCT in a Taiwanese cohort and evaluate possible prognostic factors. Methods: From the database of the Taiwan Blood and Marrow Transplantation registry, data on 396 patients with MM who underwent ASCT were reviewed. Results: The average age of participants was 54.8 years, and there were more men than women (57.6% vs. 42.4%). Most patients were diagnosed with IgG-type myeloma (52.4%), followed by IgA-type (23.2%) and light-chain type (21.4%). Patients with Durie Salmon Staging System (DSS) III disease accounted for 61.9% of the study cohort, while 23.7% had stage II and 14.4% had stage I disease. The median progression-free survival (PFS) and overall survival (OS) after ASCT were 46.5 months and 70.4 months, respectively. DSS III was a poor prognostic factor affecting both PFS and OS with a duration of 35.9 months and 69.0 months, respectively, compared with the other two stages (p = 0.006 and p = 0.03, respectively). In addition, patients with better treatment response before ASCT had better PFS and OS compared with those who did not show a response (both p < 0.0001). The overall incidence of organ toxicities associated with transplantation was low. Conclusion: In conclusion, our cohort showed that myeloma patients with early DSS and better treatment response before ASCT had better long-term survival outcomes.

AB - © 2018 Background/Purpose: Multiple myeloma (MM) is a monoclonal plasma cell malignancy. The primary choice of treatment for MM is induction therapy followed by autologous stem cell transplantation (ASCT). This study aimed to analyze the treatment efficacy of ASCT in a Taiwanese cohort and evaluate possible prognostic factors. Methods: From the database of the Taiwan Blood and Marrow Transplantation registry, data on 396 patients with MM who underwent ASCT were reviewed. Results: The average age of participants was 54.8 years, and there were more men than women (57.6% vs. 42.4%). Most patients were diagnosed with IgG-type myeloma (52.4%), followed by IgA-type (23.2%) and light-chain type (21.4%). Patients with Durie Salmon Staging System (DSS) III disease accounted for 61.9% of the study cohort, while 23.7% had stage II and 14.4% had stage I disease. The median progression-free survival (PFS) and overall survival (OS) after ASCT were 46.5 months and 70.4 months, respectively. DSS III was a poor prognostic factor affecting both PFS and OS with a duration of 35.9 months and 69.0 months, respectively, compared with the other two stages (p = 0.006 and p = 0.03, respectively). In addition, patients with better treatment response before ASCT had better PFS and OS compared with those who did not show a response (both p < 0.0001). The overall incidence of organ toxicities associated with transplantation was low. Conclusion: In conclusion, our cohort showed that myeloma patients with early DSS and better treatment response before ASCT had better long-term survival outcomes.

KW - Multiple myeloma

KW - Survival

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85051527615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051527615&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2018.07.020

DO - 10.1016/j.jfma.2018.07.020

M3 - Article

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

ER -